{
  "sample_id": "naufal_tsabitul_azmi_2026-10-05_reteplase_dsbc55_v1",
  "sample_type": "experimental",
  "reagent_list": {
    "amino_acid_mix_17": 400,
    "ammonium_glutamate": 200,
    "atp": 250,
    "base_buffer": 2000,
    "coa": 100,
    "ctp": 175,
    "dsbc_ecoli": 1100,
    "folinic_acid": 50,
    "gtp": 175,
    "hepes_koh": 550,
    "lysate": 5000,
    "magnesium_glutamate": 225,
    "nad": 75,
    "nuclease_free_water": 525,
    "oxidized_glutathione": 475,
    "pep_mono": 6000,
    "potassium_oxalate": 150,
    "putrescine": 50,
    "reduced_glutathione": 200,
    "spermidine": 125,
    "utp": 175,
    "template_reteplase": 2000
  },
  "metadata": {
    "ai_model": "Codex desktop",
    "protein_target": "Reteplase",
    "acknowledgements": "Ginkgo Reteplase PEP reference Reteplase_R2PC_041; class-provided DSB lysate and fixed GSSG/GSH framework.",
    "comments": "HW3 initial hypothesis: increase purified DsbC from 5.0 to 5.5 uM (1000 to 1100 nL of 100-uM stock), reducing water from 625 to 525 nL. Keep all other Reteplase PEP additives, including GSSG and GSH, fixed. Use the supplied DSB lysate; no student IAM treatment is added. Test whether greater disulfide-isomerization capacity improves the active fraction. Platform estimated cost increases from $6.89 to $7.45 per reaction as mixed; activity must improve by more than approximately 8.2% at unchanged assay conditions to improve cost/activity. This is a hypothesis, not an experimental result."
  }
}